If a patient dies while being treated with an investigational drug, biological product, or device, or an individualized investigational treatment, the patient’s heirs are not liable for any outstanding debt related to the treatment or lack of insurance due to the treatment.

Section amended

2017 Acts, ch 130, §5; 2025 Acts, ch 80, §4